tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Vera Therapeutics price target raised to $97 from $75 at Evercore ISI
PremiumThe FlyVera Therapeutics price target raised to $97 from $75 at Evercore ISI
8d ago
Vera Therapeutics price target raised to $73 from $60 at TD Cowen
Premium
The Fly
Vera Therapeutics price target raised to $73 from $60 at TD Cowen
11d ago
Optimistic Buy Rating for Vera Therapeutics Amid Strategic Advancements and Financial Projections
Premium
Ratings
Optimistic Buy Rating for Vera Therapeutics Amid Strategic Advancements and Financial Projections
12d ago
Vera Therapeutics Appoints James R. Meyers to Board
PremiumCompany AnnouncementsVera Therapeutics Appoints James R. Meyers to Board
20d ago
Optimistic Buy Rating for Vera Therapeutics Driven by Atacicept’s Commercial Potential and Favorable Valuation
Premium
Ratings
Optimistic Buy Rating for Vera Therapeutics Driven by Atacicept’s Commercial Potential and Favorable Valuation
20d ago
Positive Market Outlook for Vera Therapeutics Driven by Atacicept’s Strategic Advantages and Favorable Regulatory Environment
Premium
Ratings
Positive Market Outlook for Vera Therapeutics Driven by Atacicept’s Strategic Advantages and Favorable Regulatory Environment
20d ago
Vera Therapeutics’ Atacicept Shows Promising Phase 3 Results and Regulatory Progress, Earning Buy Rating
PremiumRatingsVera Therapeutics’ Atacicept Shows Promising Phase 3 Results and Regulatory Progress, Earning Buy Rating
1M ago
Vera Therapeutics Announces Promising Phase 3 Trial Results
Premium
Company Announcements
Vera Therapeutics Announces Promising Phase 3 Trial Results
1M ago
Vera Therapeutics reports ‘positive’ data from ORIGIN Phase 3 trial of atacicept
Premium
The Fly
Vera Therapeutics reports ‘positive’ data from ORIGIN Phase 3 trial of atacicept
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100